The DAC system and associations with multiple myeloma

Investigational New Drugs

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Ocio, Enrique M ^a,b   San Miguel, Jesús F ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b CSIC   (Spain)

Author keywords

Bortezomib; DACi; Deacetylases; Dexamethasone; HDACi; Lenalidomide; Multiple myeloma

Indexed keywords

ANGIOGENESIS INHIBITOR; BORTEZOMIB; DACINOSTAT; DEXAMETHASONE; DOXORUBICIN; ENTINOSTAT; GIVINOSTAT; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; JNJ 26481585; LENALIDOMIDE; MOCETINOSTAT; NUCLEAR RECEPTOR NUR77; PANOBINOSTAT; PDX 101; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P53; RESMINOSTAT; ROMIDEPSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE ARREST; CYTOPENIA; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ECG ABNORMALITY; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MULTIPLE MYELOMA;

EID: 78651350825     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-010-9589-x     Document Type: Article

References (88)

1. RA Kyle SV Rajkumar 2004 Multiple myeloma N Engl J Med 351 1860 1873 1:CAS:528:DC%2BD2cXptFChtLk%3D 10.1056/NEJMra041875 15509819 (Pubitemid 39426321)
2. NJ Petrelli EP Winer J Brahmer, et al. 2009 Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology J Clin Oncol 27 6052 6069 10.1200/JCO.2009.26.6171 19901123
3. RA Kyle SV Rajkumar 2008 Multiple myeloma Blood 111 2962 2972 1:CAS:528:DC%2BD1cXjvVamt7w%3D 10.1182/blood-2007-10-078022 18332230
4. SK Kumar SV Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 1:CAS:528:DC%2BD1cXivFaktrk%3D 10.1182/blood-2007-10-116129 17975015
5. PG Richardson P Sonneveld MW Schuster, et al. 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 2498 1:CAS:528:DC%2BD2MXltlaksLc%3D 10.1056/NEJMoa043445 15958804 (Pubitemid 41007864)
6. S Singhal J Mehta R Desikan, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565 1571 1:CAS:528:DyaK1MXotVSgs78%3D 10.1056/NEJM199911183412102 10564685
7. M Dimopoulos A Spencer M Attal, et al. 2007 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123 2132 1:CAS:528:DC%2BD2sXhtlGis7nN 10.1056/NEJMoa070594 18032762 (Pubitemid 350146107)
8. DM Weber C Chen R Niesvizky, et al. 2007 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133 2142 1:CAS:528:DC%2BD2sXhtlGis7bM 10.1056/NEJMoa070596 18032763 (Pubitemid 350146108)
9. EM Ocio MV Mateos P Maiso A Pandiella JF San-Miguel 2008 New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings Lancet Oncol 9 1157 1165 1:CAS:528:DC%2BD1cXhsVWrsL7K 10.1016/S1470-2045(08)70304-8 19038762
10. CS Mitsiades T Hideshima D Chauhan, et al. 2009 Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib Semin Hematol 46 166 175 1:CAS:528:DC%2BD1MXmt1WhtLw%3D 10.1053/j.seminhematol.2009.02.003 19389500
11. IV Gregoretti YM Lee HV Goodson 2004 Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J Mol Biol 338 17 31 1:CAS:528:DC%2BD2cXisFyksro%3D 10.1016/j.jmb.2004.02.006 15050820 (Pubitemid 38429783)
12. M Dokmanovic C Clarke PA Marks 2007 Histone deacetylase inhibitors: overview and perspectives Mol Cancer Res 5 981 989 1:CAS:528:DC%2BD2sXhtFygsLvN 10.1158/1541-7786.MCR-07-0324 17951399 (Pubitemid 350080267)
13. AJ de Ruijter AH van Gennip HN Caron S Kemp AB van Kuilenburg 2003 Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem J 370 737 749 10.1042/BJ20021321 12429021 (Pubitemid 36399066)
14. O Witt HE Deubzer T Milde I Oehme 2009 HDAC family: What are the cancer relevant targets? Cancer Lett 277 8 21 1:CAS:528:DC%2BD1MXjtFOhsL4%3D 10.1016/j.canlet.2008.08.016 18824292
15. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 769 784 1:CAS:528: DC%2BD28XptVCltrY%3D 10.1038/nrd2133 16955068 (Pubitemid 44348499)
16. S Minucci PG Pelicci 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 38 51 1:CAS:528:DC%2BD28Xht1GgsA%3D%3D 10.1038/nrc1779 16397526 (Pubitemid 43054973)
17. WS Xu RB Parmigiani PA Marks 2007 Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 5541 5552 1:CAS:528: DC%2BD2sXovFersrY%3D 10.1038/sj.onc.1210620 17694093 (Pubitemid 47255934)
18. C Hubbert A Guardiola R Shao, et al. 2002 HDAC6 is a microtubule- associated deacetylase Nature 417 455 458 1:CAS:528:DC%2BD38XjvVersr4%3D 10.1038/417455a 12024216 (Pubitemid 34563539)
19. AD Tran TP Marmo AA Salam, et al. 2007 HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions J Cell Sci 120 1469 1479 1:CAS:528:DC%2BD2sXlsFSjtbs%3D 10.1242/jcs.03431 17389687 (Pubitemid 46780039)
20. P Bali M Pranpat J Bradner, et al. 2005 Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 26729 26734 1:CAS:528:DC%2BD2MXmt1Ggs7w%3D 10.1074/jbc.C500186200 15937340 (Pubitemid 41040705)
21. M Esteller 2008 Epigenetics in cancer N Engl J Med 358 1148 1159 1:CAS:528:DC%2BD1cXjt1ahs7Y%3D 10.1056/NEJMra072067 18337604 (Pubitemid 351398489)
22. W Weichert A Roske V Gekeler, et al. 2008 Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis Lancet Oncol 9 139 148 1:CAS:528:DC%2BD1cXhsVOnu7c%3D 10.1016/S1470-2045(08)70004-4 18207460
23. W Weichert A Roske S Niesporek, et al. 2008 Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo Clin Cancer Res 14 1669 1677 1:CAS:528:DC%2BD1cXjtlejt7o%3D 10.1158/1078-0432.CCR-07-0990 18347167 (Pubitemid 351469450)
24. W Weichert A Roske V Gekeler, et al. 2008 Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy Br J Cancer 98 604 610 1:CAS:528:DC%2BD1cXhs1Krsbo%3D 10.1038/sj.bjc.6604199 18212746 (Pubitemid 351214528)
25. P Marks RA Rifkind VM Richon R Breslow T Miller WK Kelly 2001 Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 1 194 202 1:CAS:528:DC%2BD38XlvF2qtr0%3D 10.1038/35106079 11902574
26. H Ozdag AE Teschendorff AA Ahmed, et al. 2006 Differential expression of selected histone modifier genes in human solid cancers BMC Genomics 7 90 10.1186/1471-2164-7-90 16638127 (Pubitemid 43852761)
27. T Sakuma K Uzawa T Onda, et al. 2006 Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma Int J Oncol 29 117 124 1:CAS:528:DC%2BD28XntlWrtr4%3D 16773191
28. S Saji M Kawakami S Hayashi, et al. 2005 Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer Oncogene 24 4531 4539 1:CAS:528: DC%2BD2MXls1Onurk%3D 10.1038/sj.onc.1208646 15806142 (Pubitemid 41032616)
29. Z Zhang H Yamashita T Toyama, et al. 2004 HDAC6 expression is correlated with better survival in breast cancer Clin Cancer Res 10 6962 6968 1:CAS:528:DC%2BD2cXpslGlur4%3D 10.1158/1078-0432.CCR-04-0455 15501975 (Pubitemid 39383047)
30. BE Linggi SJ Brandt ZW Sun SW Hiebert 2005 Translating the histone code into leukemia J Cell Biochem 96 938 950 1:CAS:528:DC%2BD2MXht1Kgur7E 10.1002/jcb.20604 16167339 (Pubitemid 41688720)
31. Y Choi KE Elagib AN Goldfarb 2005 AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein Crit Rev Eukaryot Gene Expr 15 207 216 1:CAS:528:DC%2BD28XltVeqtw%3D%3D 16390317
32. JM Amann J Nip DK Strom, et al. 2001 ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain Mol Cell Biol 21 6470 6483 1:CAS:528:DC%2BD3MXmvFGhsLs%3D 10.1128/MCB.21.19.6470-6483.2001 11533236 (Pubitemid 32927415)
33. A Atsumi A Tomita H Kiyoi T Naoe 2006 Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo Biochem Biophys Res Commun 345 1471 1480 1:CAS:528:DC%2BD28Xltl2gsL0%3D 10.1016/j.bbrc.2006.05.047 16730330 (Pubitemid 43817898)
34. A Chauchereau M Mathieu SJ de Saintignon, et al. 2004 HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF Oncogene. 23 8777 8784 1:CAS:528:DC%2BD2cXpvV2rtbw%3D 10.1038/sj.onc.1208128 15467736 (Pubitemid 39593292)
35. W Xiong X Wu S Starnes, et al. 2008 An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma Blood 112 4235 4246 1:CAS:528:DC%2BD1cXhsVSmsrvE 10.1182/blood-2007-10-119123 18337559
36. NC Gutierrez MV Castellanos ML Martin, et al. 2007 Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis Leukemia 21 143 150 1:CAS:528:DC%2BD28XhtlSqurzK 10.1038/sj.leu.2404413 17024116 (Pubitemid 44921845)
37. H Chang C Qi QL Yi D Reece AK Stewart 2005 p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation Blood 105 358 360 1:CAS:528:DC%2BD2MXis1KisQ%3D%3D 10.1182/blood-2004-04-1363 15339849 (Pubitemid 40053104)
38. WJ Chng T Price-Troska N Gonzalez-Paz, et al. 2007 Clinical significance of TP53 mutation in myeloma Leukemia 21 582 584 1:CAS:528:DC%2BD2sXhvFWksb0%3D 10.1038/sj.leu.2404524 17215851
39. EM Ocio P Maiso X Chen, et al. 2009 Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks Blood 113 3781 3791 1:CAS:528:DC%2BD1MXlt1yjsb4%3D 10.1182/blood-2008-09-177774 19020308
40. EM Hurt SB Thomas B Peng WL Farrar 2006 Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator Cancer Biol Ther 5 1154 1160 1:CAS:528:DC%2BD2sXktleitg%3D%3D 10.1158/1535-7163.MCT-05-0446 16855375 (Pubitemid 43881307)
41. EL Davenport HE Moore AS Dunlop, et al. 2007 Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells Blood 110 2641 2649 1:CAS:528:DC%2BD2sXhtFCnsbnM 10.1182/blood-2006-11-053728 17525289 (Pubitemid 47523188)
42. EL Davenport GJ Morgan FE Davies 2008 Untangling the unfolded protein response Cell Cycle 7 865 869 1:CAS:528:DC%2BD1cXnslWqs7s%3D 10.4161/cc.7.7.5615 18414035
43. EJ Bennett NF Bence R Jayakumar RR Kopito 2005 Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation Mol Cell 17 351 365 1:CAS:528: DC%2BD2MXhs1OitrY%3D 10.1016/j.molcel.2004.12.021 15694337 (Pubitemid 40193307)
44. RR Kopito 2000 Aggresomes, inclusion bodies and protein aggregation Trends Cell Biol 10 524 530 1:CAS:528:DC%2BD3cXot12ltL0%3D 10.1016/S0962- 8924(00)01852-3 11121744
45. Y Kawaguchi JJ Kovacs A McLaurin JM Vance A Ito TP Yao 2003 The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress Cell 115 727 738 1:CAS:528:DC%2BD3sXhtVWgurfL 10.1016/S0092-8674(03)00939-5 14675537 (Pubitemid 38030301)
46. TA Miller DJ Witter S Belvedere 2003 Histone deacetylase inhibitors J Med Chem 46 5097 5116 1:CAS:528:DC%2BD3sXosVCktbg%3D 10.1021/jm0303094 14613312 (Pubitemid 37414179)
47. WK Rasheed RW Johnstone HM Prince 2007 Histone deacetylase inhibitors in cancer therapy Expert Opin Investig Drugs 16 659 678 1:CAS:528: DC%2BD2sXks1aht78%3D 10.1517/13543784.16.5.659 17461739 (Pubitemid 46729100)
48. SJ Haggarty KM Koeller JC Wong CM Grozinger SL Schreiber 2003 Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proc Natl Acad Sci USA 100 4389 4394 1:CAS:528:DC%2BD3sXjt12gtL0%3D 10.1073/pnas.0430973100 12677000 (Pubitemid 36457739)
49. N Mitsiades CS Mitsiades PG Richardson, et al. 2003 Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 101 4055 4062 1:CAS:528:DC%2BD3sXktVGnu7w%3D 10.1182/blood-2002-11-3514 12531799 (Pubitemid 36857886)
50. CS Mitsiades NS Mitsiades CJ McMullan, et al. 2004 Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci USA 101 540 545 1:CAS:528: DC%2BD2cXmsFGnsA%3D%3D 10.1073/pnas.2536759100 14695887 (Pubitemid 38084672)
51. D Lavelle YH Chen M Hankewych J DeSimone 2001 Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression Am J Hematol 68 170 178 1:CAS:528:DC%2BD3MXnvF2ltr4%3D 10.1002/ajh.1174 11754398 (Pubitemid 32983205)
52. L Catley E Weisberg YT Tai, et al. 2003 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 2615 2622 1:CAS:528:DC%2BD3sXnslykurY%3D 10.1182/blood-2003-01-0233 12816865 (Pubitemid 37193603)
53. SB Khan T Maududi K Barton J Ayers S Alkan 2004 Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma Br J Haematol 125 156 161 1:CAS:528:DC%2BD2cXktlKrsL8%3D 10.1111/j.1365-2141.2004. 04882.x 15059137 (Pubitemid 38534966)
54. M Kaiser I Zavrski J Sterz, et al. 2006 The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma Haematologica 91 248 251 1:CAS:528: DC%2BD28XisFWrsLY%3D 16461312
55. C Schwartz V Palissot N Aouali, et al. 2007 Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines Int J Oncol 30 573 582 1:CAS:528:DC%2BD2sXjtFGgt7w%3D 17273758
56. K Kitazoe M Abe M Hiasa, et al. 2009 Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma Int J Hematol 89 45 57 1:CAS:528:DC%2BD1MXkvVWjtg%3D%3D 10.1007/s12185-008-0226-9 19093163
57. P Neri P Tagliaferri MT Di Martino, et al. 2008 In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor Br J Haematol 143 520 531 1:CAS:528:DC%2BD1MXms1Wi 18986388
58. L Catley E Weisberg T Kiziltepe, et al. 2006 Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 3441 3449 1:CAS:528:DC%2BD28Xht1ahsLzM 10.1182/blood-2006-04-016055 16728695
59. P Maiso X Carvajal-Vergara EM Ocio, et al. 2006 The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance Cancer Res 66 5781 5789 1:CAS:528:DC%2BD28XltFyjtb8%3D 10.1158/0008-5472.CAN-05- 4186 16740717 (Pubitemid 43927132)
60. Ocio EM, Vilanova D, Atadja P et al (2009) In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica
61. R Feng A Oton MY Mapara G Anderson C Belani S Lentzsch 2007 The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage Br J Haematol 139 385 397 1:CAS:528:DC%2BD2sXhtlOhtL7P 10.1111/j.1365-2141.2007.06772.x 17910628 (Pubitemid 47512171)
62. J Arts P Angibaud A Marien, et al. 2007 R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies Br J Cancer 97 1344 1353 1:CAS:528:DC%2BD2sXht1yku7fJ 10.1038/sj.bjc.6604025 18000499 (Pubitemid 350114783)
63. R Feng H Ma CA Hassig, et al. 2008 KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling Mol Cancer Ther 7 1494 1505 1:CAS:528: DC%2BD1cXnsVSktLw%3D 10.1158/1535-7163.MCT-08-0183 18566220
64. S Deleu M Lemaire J Arts, et al. 2009 The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models Leukemia 23 1894 1903 1:CAS:528:DC%2BD1MXht1GgtLjO 10.1038/leu.2009.121 19494837
65. Todoerti K, Barbui V, Pedrini O et al Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 95:260-269
66. Mandl-Weber S, Meinel F, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol
67. TE Fandy S Shankar DD Ross E Sausville RK Srivastava 2005 Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma Neoplasia 7 646 657 1:CAS:528:DC%2BD2MXps1CntL4%3D 10.1593/neo.04655 16026644 (Pubitemid 41099418)
68. M Akiyama T Hideshima T Hayashi, et al. 2002 Cytokines modulate telomerase activity in a human multiple myeloma cell line Cancer Res 62 3876 3882 1:CAS:528:DC%2BD38XltF2ju7k%3D 12097303
69. S Chen Y Dai XY Pei S Grant 2009 Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1 Mol Cell Biol 29 6149 6169 1:CAS:528:DC%2BD1MXhsV2ltLbK 10.1128/MCB.01481-08 19805519
70. JS Damiano AE Cress LA Hazlehurst AA Shtil WS Dalton 1999 Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines Blood 93 1658 1667 1:CAS:528:DyaK1MXhsFeru7c%3D 10029595
71. T Hideshima C Mitsiades G Tonon PG Richardson KC Anderson 2007 Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets Nat Rev Cancer 7 585 598 1:CAS:528:DC%2BD2sXotVKqsrw%3D 10.1038/nrc2189 17646864 (Pubitemid 47106630)
72. JL Wolf D Siegel J Matous, et al. 2008 A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma ASH Annu Meet Abstr 112 2774
73. P Richardson C Mitsiades K Colson, et al. 2008 Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leuk Lymphoma 49 502 507 1:CAS:528:DC%2BD1cXit1Cmsbc%3D 10.1080/10428190701817258 18297527 (Pubitemid 351298334)
74. Galli M, Salmoiraghi S, Golay J et al A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 89:185-190
75. R Niesvizky S Ely M DiLiberto, et al. 2005 Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM) ASH Annu Meet Abstr 106 2574-
76. Campbell RA, Sanchez E, Steinberg J et al Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 84:201-211
77. S Deleu M Lemaire J Arts, et al. 2009 Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma Cancer Res 69 5307 5311 1:CAS:528:DC%2BD1MXnvFWqu74%3D 10.1158/0008-5472.CAN-08-4472 19531653
78. T Hideshima JE Bradner J Wong, et al. 2005 Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci USA 102 8567 8572 1:CAS:528: DC%2BD2MXlsFCgtro%3D 10.1073/pnas.0503221102 15937109 (Pubitemid 40862776)
79. XY Pei Y Dai S Grant 2004 Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clin Cancer Res 10 3839 3852 1:CAS:528:DC%2BD2cXksVKnt7g%3D 10.1158/1078-0432.CCR-03-0561 15173093 (Pubitemid 38697620)
80. A Badros AM Burger S Philip, et al. 2009 Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 5250 5257 1:CAS:528:DC%2BD1MXpvFeit7Y%3D 10.1158/1078-0432.CCR-08- 2850 19671864
81. D Weber AZ Badros S Jagannath, et al. 2008 Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience ASH Annu Meet Abstr 112 871
82. DM Weber S Jagannath R Sobecks, et al. 2008 Combination of vorinostat plus bortezomib for the treatment of patients with multiple myeloma who have previously received bortezomib ASH Annu Meet Abstr 112 3711
83. JF San-Miguel O Sezer D Siegel, et al. 2009 A phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma ASH Annu Meet Abstr 114 3852-
84. SJ Harrison H Quach K Yuen, et al. 2008 High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial ASH Annu Meet Abstr 112 3698
85. PM Voorhees C Gasparetto KL Richards, et al. 2009 Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: results of a phase I study ASH Annu Meet Abstr 114 306-
86. Spencer A, Lonial S, Taylor K et al (2009) Panobinostat and lenalidomide combination phase I trial in myeloma. Clin Lymphoma Myeloma. Abstract 329
87. D Siegel DM Weber CS Mitsiades, et al. 2009 Combined vorinostat, lenalidomide and dexamethasone therapy in patients with relapsed or refractory multiple myeloma: a phase I study ASH Annu Meet Abstr 114 305-
88. JR Berenson O Yellin RV Boccia Y Nassir S Rothstein RA Swift 2009 A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM) ASH Annu Meet Abstr 114 1855-